Table 2.

Effects and costs (in American dollars) of the cost‐effective strategies per age cohort. The number of screens, recurrences and progression, costs and QALYs gained are given per patient over a lifetime, without discount. In the calculation of the ICER a 3% discount rate was used

Start age, years	Frequency, months	Duration, years	Screens, n	Recurrence, n	Progression, n	Costs, $	QALYs	ICER, $
65	24	2	0.91	0.17	0.11	1 264	1.87	920
65	24	5	2.46	0.39	0.26	3 050	3.99	1 123
65	12	5	4.51	0.55	0.19	3 017	3.86	1 145
65	12	10	8.14	0.87	0.30	4 984	5.60	1 450
65	12	Lifetime	14.34	1.19	0.41	7 374	6.60	2 786
65	6	Lifetime	30.01	1.78	0.31	10 050	7.12	4 999
65	3	Lifetime	60.59	2.27	0.20	14 973	7.29	24 758
70	12	2	1.86	0.25	0.08	1 329	1.53	1 112
70	12	5	4.36	0.53	0.18	2 924	2.98	1 445
70	12	10	7.66	0.82	0.28	4 709	4.15	2 177
70	12	Lifetime	11.66	1.05	0.36	6 327	4.62	4 579
70	6	Lifetime	24.49	1.54	0.27	8 429	5.06	4 675
70	3	Lifetime	49.65	1.92	0.17	12 405	5.22	20 195
75	12	2	1.81	0.24	0.08	1 288	1.13	1 410
75	12	5	4.13	0.50	0.17	2 770	2.11	1 932
75	12	10	6.90	0.75	0.26	4 276	2.76	3 237
75	6	10	14.38	1.03	0.18	5 306	3.00	4 147
75	6	Lifetime	19.13	1.27	0.22	6 770	3.26	7 340
75	3	Lifetime	38.94	1.56	0.14	9 841	3.40	19 065
80	12	2	1.71	0.23	0.08	1 217	0.75	1 958
80	12	5	3.74	0.46	0.16	2 517	1.30	2 918
80	6	5	7.76	0.60	0.10	2 990	1.42	3 895
80	6	10	12.10	0.88	0.15	4 494	1.78	5 502
80	6	Lifetime	14.09	0.98	0.17	5 122	1.83	15 572
80	3	Lifetime	28.83	1.19	0.11	7 364	1.94	19 402
85	12	2	1.53	0.20	0.07	1 092	0.41	3 112
85	6	2	3.86	0.31	0.05	1 528	0.53	4 118
85	6	5	6.54	0.51	0.09	2 526	0.75	5 404
85	6	10	9.07	0.67	0.12	3 406	0.85	11 558
85	3	10	18.63	0.80	0.07	4 824	0.92	20 914